Foundation Fighting Blindness

Lindsey Rambo, a special education teaching assistant, mom, and wife, talks to host Ben Shaberman about her journey with Leber congenital amaurosis 5 (LCA5), participation in Opus Genetics' LCA5 gene therapy clinical trial, and her appearance on Good Morning America to tell her story about meaningful vision improvements.

The company has also fully enrolled the Phase 2/3 VISTA clinical trial for its XLRP gene therapy.

Dr. Deniz Dalkara, a research director at INSERM in France, talks to hose Ben Shaberman about her emerging gene-agnostic, gene therapy designed to restore cone-mediated vision in people with advanced retinitis pigmentosa. Known as SPVN20 and clinically developed by SparingVision, the treatment recently moved into a clinical trial in Europe. Dr. Dakara also discusses her earlier work in retinal gene and optogenetic therapy development.

Tinlarebant slowed disease progression by 36 percent in the Dragon Phase 3 clinical trial.

The Foundation funded preclinical studies for the approach and launched Opus.